BOSTON, Oct. 5, 2016 - Havas Health, part of Havas Group and a global communications company operating in over 50 countries focused on health and wellness communications and cross stakeholder strategy, and Vencore, a company with a 40-year history of defense-grade analytics for the department of defense, announce the formation of HVH Patient Precision Analytics (HVH). This first-of-its-kind entity will leverage sophisticated analytics and predictive modeling with deep therapeutic area expertise that will provide unique data and insights into the rare and niche disease market.
As part of the new venture, HVH is now launching its first service offering to enable biopharma commercial leaders to find undiagnosed patients with a rare disease. By leveraging large amounts of disparate health data, HVH collects, aggregates and analyzes the journeys of known patients helping to inform early diagnosis and intervention of undiagnosed patients with a rare disease at the MSA, zip code or physician level. HVH is the only analytics provider in the market that uses proven predictive modeling combined with medical expertise to offer solutions that are clinically meaningful.
The joint venture will be led by Steve Costalas from Vencore, who will serve as chief executive officer, and Jeff Ceitlin from Havas Health, who will serve as chief commercial officer.
"This joint venture gives our proven defense-grade patient finder technology increased breadth and scale to better serve the pharmaceutical industry," said Costalas. "Our potentially life-saving analytical tools will assist the earlier identification and diagnosis of disease in patients across the country."
To learn more about HVH, visit www.HVHprecision.com.